Hypertension and Vascular Research Division, Department of Internal Medicine, Henry Ford Hospital, Detroit, Michigan 48202, USA.
Am J Physiol Heart Circ Physiol. 2011 Mar;300(3):H1053-61. doi: 10.1152/ajpheart.00772.2010. Epub 2010 Dec 30.
Our laboratory previously reported that inducible PGE(2) synthase, mPGES-1, contributes to micromolar production of PGE(2) in neonatal ventricular myocytes in vitro, which stimulates their growth. We therefore hypothesized that mPGES-1 contributes to cardiac hypertrophy following angiotensin II (ANG II) infusion. To test this hypothesis, we used 10- to 12-wk-old mPGES-1 knockout mice (mPGES-1 KO) and C57Bl/6 control mice infused for 8 wk with either 1.4 mg · kg(-1) · day(-1) ANG II or vehicle subcutaneously. Blood pressure [systolic blood pressure (SBP)] was measured throughout the study, and cardiac function was assessed by M-mode echocardiography at baseline and at 8 wk of infusion. At the conclusion of the study, immunohistochemistry was used to evaluate collagen fraction, myocyte cross-sectional area (MCSA), and apoptosis. At baseline, there was no difference in SBP between mPGES-1 KO mice and C57BL/6 controls. ANG II infusion increased SBP to similar levels in both strains. In control mice, infusion of ANG II increased MCSA and posterior wall thickness at diastole (PWTd) but had little effect on cardiac function, consistent with compensatory hypertrophy. In contrast, cardiac function was worse in mPGES-1 KO mice after ANG II treatment. Ejection fraction declined from 76.2 ± 2.7 to 63.3 ± 3.4% after ANG II, and left ventricular dimension at systole and diastole increased from 1.29 ± 0.02 to 1.78 ± 0.15 mm and from 2.57 ± 0.03 to 2.90 ± 0.13 mm, respectively. Infusion of ANG II increased both the LV-to-body weight and the mass-to-body weight ratios to a similar extent in both strains. However, PWTd increased by a lesser extent in KO mice, suggesting an impaired hypertrophic response. ANG II infusion increased collagen staining similarly in both strains, but TdT-dUTP nick end labeling staining was greater in mPGES-1 KO mice. Overall, these results are consistent with a beneficial effect for mPGES-1 in the maintenance of cardiac function in ANG II-dependent hypertension.
我们的实验室先前报道,诱导型前列腺素 E2 合酶(mPGES-1)有助于体外新生心室肌细胞中前列腺素 E2(PGE2)的毫摩尔级产生,从而刺激其生长。因此,我们假设 mPGES-1 有助于血管紧张素 II(ANG II)输注后的心脏肥大。为了验证这一假设,我们使用了 10-12 周龄的 mPGES-1 敲除小鼠(mPGES-1 KO)和 C57Bl/6 对照小鼠,通过皮下注射 1.4 mg·kg-1·day-1 的 ANG II 或载体进行 8 周输注。在整个研究过程中测量血压(收缩压[SBP]),并通过 M 型超声心动图在基线和输注 8 周时评估心功能。在研究结束时,使用免疫组织化学评估胶原分数、心肌细胞横截面积(MCSA)和细胞凋亡。在基线时,mPGES-1 KO 小鼠和 C57BL/6 对照小鼠之间的 SBP 没有差异。ANG II 输注使两种品系的 SBP 升高到相似水平。在对照小鼠中,ANG II 输注增加了心肌细胞横截面积和舒张末期后壁厚度(PWTd),但对心功能影响不大,与代偿性肥大一致。相比之下,在 ANG II 治疗后,mPGES-1 KO 小鼠的心功能更差。射血分数从 76.2±2.7%下降到 63.3±3.4%,左心室收缩和舒张末期直径分别从 1.29±0.02mm 增加到 1.78±0.15mm 和从 2.57±0.03mm 增加到 2.90±0.13mm。ANG II 输注使两种品系的 LV 与体重比和质量与体重比均以相似的程度增加。然而,KO 小鼠的 PWTd 增加幅度较小,提示其肥大反应受损。ANG II 输注使两种品系的胶原染色均增加,但 TdT-dUTP 末端标记染色在 mPGES-1 KO 小鼠中更大。总体而言,这些结果与 mPGES-1 在 ANG II 依赖性高血压中心功能维持中的有益作用一致。